Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
Alessandro Lucchesi, Consultant Hematologist at Romagna Scientific Institute for the Study and Treatment of Cancer (I.R.S.T.) Ltd., shared a post on LinkedIn:
“The programme for RiseMPN 2026 is final, and it is online.
One question runs through both days: can we engineer disease trajectories in MPNs? Not whether a drug works, but which combinations, in which patients, at which moment, can genuinely rewrite the natural history of the disease.
Rome, 6 and 7 November.
Single track, no parallel sessions, because everyone should leave having heard the same arguments.
Ten sessions, two Rise Lectures, two Bridge Lectures and a transatlantic Strategic Dialogue, with more than fifty faculty from across Europe and the United States.
Tiziano Barbui opens the congress on risk as a trajectory rather than a static score.
Giovanni Martinelli asks how to starve a myeloid clone. Between those two poles: mechanism, combination, trajectory.
The call for abstracts closes on 20 October.
The Best Poster Award carries full hospitality for RiseMPN 2027, because young investigators deserve to be brought back rather than thanked once.
Registration is free.
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines